Overview

Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) represents a transformative advancement in HIV prevention. By shifting from daily oral dosing to extended-interval injectable options, LAI-PrEP expands patient choice, improves adherence potential, and strengthens equitable access to prevention.

This IAPAC Learning Academy module equips clinicians with practical, evidence-informed guidance to support the implementation of LAI-PrEP in diverse care settings.

Purpose

This session is designed to strengthen clinicians’ knowledge, confidence, and clinical judgment in applying evidence-based, person-centered, and equitable approaches to LAI-PrEP delivery.

Our goal is to ensure that clinicians feel prepared to:

  • Integrate long-acting PrEP into routine clinical practice

  • Support shared decision-making and patient autonomy

  • Address structural and social barriers to prevention

  • Advance health equity in HIV prevention services

Learning Objectives

After completing this module, participants should be able to:

  1. Describe the pharmacology and administration of currently available LAI-PrEP agents.

  2. Summarize efficacy and safety findings from pivotal studies, including HPTN 083, HPTN 084, and the PURPOSE 1 and PURPOSE 2 studies.

  3. Implement LAI-PrEP using shared decision-making models that prioritize patient preference, autonomy, and equity.

Supplemental Reading

Centers for Disease Control and Prevention (CDC). (2024). HIV Surveillance Report 2024. Atlanta, GA: U.S. Department of Health and Human Services.
Available at: https://www.cdc.gov/nchhstp/director-letters/cdc-publishes-new-hiv-surveillance-reports.html

Centers for Disease Control and Prevention (CDC). (2024). Clinical Guidance for PrEP. Atlanta, GA: U.S. Department of Health and Human Services.
Available at: https://www.cdc.gov/hivnexus/hcp/prep/index.html

Delany-Moretlwe S, Hughes JP, Bock P, et al. (2022). Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022.
Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9077443/

Landovitz RJ, Donnell D, Clement ME, et al. (2021). Cabotegravir for HIV prevention in cisgender men and transgender women. New England Journal of Medicine, 385: 595–608.
Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2101016

National Alliance of State and Territorial AIDS Directors (NASTAD). Long-Acting Injectable PrEP.
Available at: https://nastad.org/long-acting-injectable-prep

PURPOSE Program Reports. (2024). Clinical trial updates on lenacapavir for HIV prevention.
Available at: https://www.gilead.com/news-and-press/press-room

UNAIDS. (2024). Global AIDS Update 2024. Geneva: Joint United Nations Programme on HIV/AIDS.
Available at: https://www.unaids.org/en/resources/documents/2024/global-aids-update-2024

World Health Organization (WHO). (2022). Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention. Geneva: WHO.
Available at: https://www.who.int/publications/i/item/9789240054097

World Health Organization (WHO). (2024). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. Geneva: WHO.
Available at: https://www.who.int/publications/i/item/9789240031593

World Health Organization (WHO). (2024). WHO Implementation Tool for Pre-Exposure Prophylaxis of HIV Infection. Geneva: WHO.
Available at: https://www.who.int/publications/i/item/9789240097230

Course Content

Modules Status